Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Receivables (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Change in Receivables for 12 consecutive years, with -$240000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 141.59% year-over-year to -$240000.0, compared with a TTM value of -$1.7 million through Sep 2025, down 284.67%, and an annual FY2024 reading of -$329000.0, up 98.99% over the prior year.
  • Change in Receivables was -$240000.0 for Q3 2025 at CytomX Therapeutics, down from -$87000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $34.2 million in Q4 2022 and bottomed at -$34.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is $43736.8, with a median of $58000.0 recorded in 2022.
  • The sharpest move saw Change in Receivables surged 35368.04% in 2022, then crashed 15141.38% in 2023.
  • Year by year, Change in Receivables stood at -$97000.0 in 2021, then soared by 35368.04% to $34.2 million in 2022, then plummeted by 97.04% to $1.0 million in 2023, then crashed by 124.58% to -$249000.0 in 2024, then increased by 3.61% to -$240000.0 in 2025.
  • Business Quant data shows Change in Receivables for CTMX at -$240000.0 in Q3 2025, -$87000.0 in Q2 2025, and -$1.1 million in Q1 2025.